Panitumumab

Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is manufactured by Amgen and marketed as Vectibix. It was approved by the U.S. Food and Drug Administration (FDA)for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite ... more

Also known as:

  • Vectibix

Medicine

ATC Code:

  • L01XC08
top ↑

Facts from the Community

From the BioVenturist base

Sales:

Amount Year Area
  • 170,000,000
  • 2007
  • 39,000,000
  • 2006
View entire collection »

Developed by:

Brand Names:

  • Vectibix

Stage of development:

Target/Biomolecule of Interest:

top ↑

We can also tell you Panitumumab is a…

If you know more about Panitumumab, you can add more facts here »

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

The original description for Panitumumab was automatically generated from Wikipedia.org licensed under the GNU Free Documentation License.
[1]
Learn more about Freebase licensing and attribution